

# International Journal of Molecular and Immuno Oncology

From the Editor's Desk

## Year End Message

Prashant Mehta<sup>1</sup>

<sup>1</sup>Department of Medical Oncology, Hematology and Blood and Marrow Transplant, Amrita Institute of Medical Sciences and Research, Faridabad, Haryana, India.



**\*Corresponding author:**

Dr. Prashant Mehta,  
Department of Medical  
Oncology, Hematology and  
Blood and Marrow Transplant,  
Amrita Institute of Medical  
Sciences and Research,  
Faridabad, Haryana, India.

prashantm@fbd.amrita.edu

Received: 24 December 2024  
Accepted: 24 December 2024  
Published: 27 December 2024

DOI  
10.25259/IJMIO\_35\_2024

Quick Response Code:



### Dear Readers,

As we near the end of another remarkable year, I want to take a moment to share my heartfelt appreciation for everyone who makes this journal possible and meaningful.

Each issue of the *International Journal of Molecular and Immuno Oncology* results from a dedicated team's tireless efforts. From the authors who share their groundbreaking research to the reviewers who lend their invaluable expertise to the editorial and publishing staff who bring it all together seamlessly. This is truly a collective achievement.

Our readers, thank you for your continued support and engagement. Your curiosity and commitment to advancing science inspire us to work harder with each issue. As we move into 2024, we focus on growing the journal's reach, enhancing its quality, and ensuring it remains a trusted source of cutting-edge discoveries in molecular immune-oncology.

On behalf of the editorial team, I wish you a joyful holiday season and a wonderful New Year. Let's look forward to another year of innovation, collaboration, and progress in our shared mission to advance science and healthcare.

With Best Wishes  
Prashant Mehta  
Editor-in-chief

**How to cite this article:** Mehta P. Year End Message. Int J Mol Immuno Oncol. 2024;9:67. doi: 10.25259/IJMIO\_35\_2024

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.  
©2024 Published by Scientific Scholar on behalf of International Journal of Molecular and Immuno Oncology